A syringe positioned horizontally above a small vial labeled “cancer vaccine” against a solid purple background.

Infographics

Outpacing cancer’s next move with faster vaccine production

Rapid DNA-to-mRNA workflows help scientists keep pace with rapidly evolving cancer through personalized vaccines.

Personalized cancer vaccines (PCVs) are built around mutations unique to each tumor, where delays can affect how quickly a vaccine reaches the clinic. High-fidelity, cell-free DNA synthesis compresses development timelines from months to weeks, enabling faster transitions from vaccine design to manufacturing and supporting the timely delivery of personalized therapies.

Download this infographic to learn:

The end-to-end workflow for PCV development
How scientists analyze tumor biopsy and sequencing data to identify patient-specific neoantigens
How high-fidelity, cell-free DNA fast-tracks vaccine production and timely re-dosing

Sponsored by

Top Image Credit:

iStock.com/MicroStockHub

OUTPACING CANCER’S NEXT MOVE

Optimize Vaccine Designs Faster with Cell-Free DNA

Scientists are racing to stay ahead of

cancer. Personalized cancer vaccines

Biopsy sample collection

(PCVs) use each patient’s unique

tumor mutations to train the immune

DAYS-WEEKS

system to recognize and destroy

cancer cells. High-fidelity, cell-free

Clinicians collect a small

DNA synthesis dramatically shortens the

tumor sample from the patient.

path from design to manufacturing — from

The sample contains cancer

months to weeks — accelerating the delivery

cells with mutations that create

abnormal proteins known

of truly personalized therapies.

as neoantigens.

These molecular fingerprint

distinguish cancer cells

Sequencing + analysis

from healthy ones and can

trigger the immune system.

WEEKS

Because neoantigens are

patient-specific, vaccines

encoding them are a form

Scientists sequence DNA and RNA from both tumor and healthy

of personalized medicine.

tissue, then compare the data to reveal tumor-specific mutations.

Bioinformatics and AI tools identify the most promising neoantigens

— mutations most likely to elicit a strong immune response, forming

the blueprint for vaccine design.

Vaccine Production

WEEKS

Researchers design DNA constructs encoding

the selected neoantigen sequences. These

constructs serve as in vitro transcription (IVT)

templates for mRNA

synthesis, allowing

researchers to rapidly

Administration to

manufacture PCVs on

patient + re-dosing

pre-validated platforms.

WEEKS

Clinicians administer the PCV to the patient.

How Elegen helps

Immune cells translate the mRNA into neoantigen

proteins, presenting them to T cells that recognize

Elegen produces high-fidelity IVT Ready

DNA through a cell-free process that includes

and destroy cancer cells. Booster doses strengthen

the addition of a poly(A) tail. With no need for

and sustain the immune response over time.

cloning, plasmid linearization, or purification

researchers can receive reaction-ready DNA

in as fast as 10 business days, accelerating

personalized vaccine workflows

How Elegen helps

ENFINA IVT-ready DNA

Elegen’s scalable DNA synthesis enables production of ENFINIA IVT

mRNA

Ready templates in quantities sufficient for multiple vaccine doses,

ensuring consistent quality and rapid turnaround for each patient.

FINISH